Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059277 | 1.00 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23059283 | 1.00 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24500614 | 0.84 | KDM4E (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23059276 | 0.80 | — | — | |
| SCHEMBL179563 | 0.79 | PDE8B (0.40) | PDE2AKDM4E | |
| SCHEMBL23059281 | 0.79 | PDE8B (0.40) | PDE2AKDM4E | |
| SCHEMBL23059282 | 0.77 | PI4KB (0.54) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15627374 | 0.77 | PI4KB (0.54) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL179551 | 0.77 | PI4KB (0.54) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24659480 | 0.76 | CYP1A2 (0.39) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ADORA2A 2834/4885ADORA1 3584/4885PI4KA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.